<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821391</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29112</org_study_id>
    <nct_id>NCT01821391</nct_id>
  </id_info>
  <brief_title>Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses</brief_title>
  <acronym>COMET2</acronym>
  <official_title>Multi-centre, Randomized, Investigator-blind, Intra-individual Active and Vehicle-controlled Study, Comparing Metvix Natural Daylight Photodynamic Therapy Versus Metvix Conventional Photodynamic Therapy in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted as a multi-centre, randomized, investigator-blind, active and
      vehicle-controlled, intra-individual study.

      The purpose of this study is to confirm that the Metvix NDL-PDT procedure is similar in
      efficacy and less painful when compared to Metvix c-PDT procedure for the treatment of mild
      and moderate AKs.

      In addition this study will include a Metvix NDL-PDT arm versus Metvix vehicle cream c PDT
      (Placebo) to assess the sensitivity of the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesion response</measure>
    <time_frame>week 12</time_frame>
    <description>percent of lesions treated at baseline in complete response at week 12</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pain Score</measure>
    <time_frame>Baseline</time_frame>
    <description>Subject self assessment of pain on a scale from 0 to 10</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>NDL-PDT/c-PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NDL-PDT/placebo c-PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NDL-PDT</intervention_name>
    <description>Metvix natural daylight photodynamic therapy</description>
    <arm_group_label>NDL-PDT/c-PDT</arm_group_label>
    <arm_group_label>NDL-PDT/placebo c-PDT</arm_group_label>
    <other_name>Metvix NDL-PDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>c-PDT</intervention_name>
    <description>Metvix conventional photodynamic therapy</description>
    <arm_group_label>NDL-PDT/c-PDT</arm_group_label>
    <other_name>Metvix c-PDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo c-PDT</intervention_name>
    <description>Metvix placebo conventional photodynamic therapy</description>
    <arm_group_label>NDL-PDT/placebo c-PDT</arm_group_label>
    <other_name>Metvix placebo c-PDT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of mild (Grade 1) and/or moderate (Grade 2) AKs on the face or the
             scalp on treated areas

          -  Subject with two symmetrical treated areas half scalps or two half faces excluding
             ears, chin, bridge of the nose, eyelids and lips inside the vermillion border): no
             more than a twofold difference in terms of total number of lesions between the two TAs

        Exclusion Criteria:

          -  Subject with clinical diagnosis of at least one severe (Grade 3) AK on treated areas

          -  Subject with pigmented AK on the treated areas

          -  Immuno-compromised Subject for idiopathic, disease specific or therapeutic reasons

          -  Subject with porphyria,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Basset Seguin, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Saint Louis France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bibiana Perez Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ram√≥n y Cajal Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rianne Gerritsen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University, Nijmegen Medical Center The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf-Markus Sziemies, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fur Dermatologie und Allergologie Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Synnerstad, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudmottagningen Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Huesca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Karlskoga</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Norrk√∂ping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actinic keratoses</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>natural daylight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

